Full-Dose Chemotherapy for Esophageal Cancer Patient under Hemodialysis
نویسندگان
چکیده
منابع مشابه
Full-dose chemotherapy for esophageal cancer patient under hemodialysis.
Accessible online at: www.karger.com/journals/nef Dear Sir, Protocol of chemotherapy, especially optimal dose of cisplatin (CDDP), is not yet well established for esophageal cancer patients under hemodialysis. We report here a successful treatment of advanced esophagus cancer with a full-dose chemotherapy and radiation therapy. A 68-year-old man, who was on maintenance hemodialysis for 7 years,...
متن کامل“Targeted” Chemotherapy for Esophageal Cancer
Citation: Abdo J, Agrawal DK and Mittal SK (2017) " Targeted " Chemotherapy for Esophageal Cancer. Due to its increasing incidence and low survival rate, esophageal cancer (EC) is now considered, even by non-medical professionals, as an extremely difficult cancer to beat akin to well-known terminal indications such as pancreatic and lung cancers. The average 5-year survival of EC is less than 1...
متن کاملPerioperative and Palliative Chemotherapy for Esophageal Cancer
Perioperative and palliative chemotherapy for esophageal carcinoma has undergone substantial changes in recent years. The implementation of trastuzumab in the treatment of HER2-positive advanced adenocarcinoma is a milestone as it marked the introduction of the first molecularly targeted treatment of gastric cancer. Current studies are investigating whether anti-HER2-directed treatment also pro...
متن کاملCXCL12/CXCR4 Gene Polymorphism as a Putative Prognostic Factor for Metastasizing Breast Cancer under Chemotherapy
The receptor and the receptor axis CXCL12 / CXCR4 are the two pairs studied in the metastasis of breast cancer. The purpose of this study was to investigate the relationship between the occurrence of CXCR4 / CXCL12 genes polymorphism and the clinical and pathological characteristics of patients with metastatic breast cancer under chemotherapy. Material and methods: Genomic DNA was extracted f...
متن کاملABVD for Hodgkin's lymphoma: full-dose chemotherapy without dose reductions or growth factors.
BACKGROUND We investigated whether administration of full-dose ABVD (Adriamycin, bleomycin, vinblastine, dacarbazine) chemotherapy without growth factors, and irrespective of the granulocyte count, caused treatment delays or increased the number of infective episodes, in patients with Hodgkin's lymphoma (HL). PATIENTS AND METHODS Thirty-eight patients with confirmed predominantly early-stage ...
متن کاملذخیره در منابع من
با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید
ژورنال
عنوان ژورنال: Nephron
سال: 2002
ISSN: 1660-8151,2235-3186
DOI: 10.1159/000065582